TORONTO, July 13, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the voting results of the special meeting of shareholders of Reunion held yesterday, July 12…

Source

Previous articleOpinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
Next articlePT423 – The Watts Connectedness Scale, The Importance of Elders, and What We Can Learn From Trees